Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 2
2019 2
2020 3
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

7 results
Results by year
Filters applied: . Clear all
Page 1
Venetoclax and Ibrutinib for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia.
Niemann CU, Levin MD, Dubois J, Kersting S, Enggaard L, Veldhuis GJ, Mous R, Mellink CHM, Dobber JA, Poulsen CB, Frederiksen H, Janssens A, Schjødt I, Dompeling EC, Ranti J, Mattsson M, Bellido M, Tran HTT, Nasserinejad K, Kater AP. Niemann CU, et al. Among authors: dobber ja. Blood. 2020 Oct 7:blood.2020008608. doi: 10.1182/blood.2020008608. Online ahead of print. Blood. 2020. PMID: 33027809 No abstract available.
Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment.
de Weerdt I, Hofland T, de Boer R, Dobber JA, Dubois J, van Nieuwenhuize D, Mobasher M, de Boer F, Hoogendoorn M, Velders GA, van der Klift M, Remmerswaal EBM, Bemelman FJ, Niemann CU, Kersting S, Levin MD, Eldering E, Tonino SH, Kater AP. de Weerdt I, et al. Among authors: dobber ja. Blood Adv. 2019 Sep 10;3(17):2642-2652. doi: 10.1182/bloodadvances.2019000360. Blood Adv. 2019. PMID: 31506282 Free PMC article.
Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 study.
Saberi Hosnijeh F, van der Straten L, Kater AP, van Oers MHJ, Posthuma WFM, Chamuleau MED, Bellido M, Doorduijn JK, van Gelder M, Hoogendoorn M, de Boer F, Te Raa GD, Kerst JM, Marijt EWA, Raymakers RAP, Koene HR, Schaafsma MR, Dobber JA, Tonino SH, Kersting SS, Langerak AW, Levin MD. Saberi Hosnijeh F, et al. Among authors: dobber ja. Exp Hematol. 2020 Sep;89:55-60.e6. doi: 10.1016/j.exphem.2020.08.002. Epub 2020 Aug 8. Exp Hematol. 2020. PMID: 32781097 Free article. Clinical Trial.
Changes in primary and secondary hemostasis in patients with CLL treated with venetoclax and ibrutinib.
Svanberg R, Ostrowski SR, Nasserinejad K, Kersting S, Dobber JA, Mattson M, Tran HTT, Levin MD, Mous R, Kater AP, Niemann CU. Svanberg R, et al. Among authors: dobber ja. Leuk Lymphoma. 2020 Dec;61(14):3422-3431. doi: 10.1080/10428194.2020.1811270. Epub 2020 Aug 31. Leuk Lymphoma. 2020. PMID: 32865439
Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL.
Kater AP, Kersting S, van Norden Y, Dubois J, Dobber JA, Mellink CH, Evers LM, Croon-de Boer F, Schreurs J, van der Spek E, Visser H, Idink C, Wittebol S, Hoogendoorn M, Tonino SH, Mobasher M, Levin MD; HOVON CLL study group.. Kater AP, et al. Among authors: dobber ja. Blood Adv. 2018 Dec 26;2(24):3566-3571. doi: 10.1182/bloodadvances.2018019422. Blood Adv. 2018. PMID: 30552161 Free PMC article.
Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia.
Kater AP, van Oers MHJ, van Norden Y, van der Straten L, Driessen J, Posthuma WFM, Schipperus M, Chamuleau MED, Nijland M, Doorduijn JK, Van Gelder M, Hoogendoorn M, De Croon F, Wittebol S, Kerst JM, Marijt EWA, Raymakers RAP, Schaafsma MR, Dobber JA, Kersting S, Levin MD; HOVON CLL study group. Kater AP, et al. Among authors: dobber ja. Haematologica. 2019 Jan;104(1):147-154. doi: 10.3324/haematol.2018.193854. Epub 2018 Aug 16. Haematologica. 2019. PMID: 30115656 Free PMC article. Clinical Trial.
Multicenter study to evaluate a new enumeration method for hematopoietic stem cell collection management.
Grommé M, Russcher H, Braakman E, Klinkspoor JH, Dobber JA, de Greef I, de Wit NCJ. Grommé M, et al. Among authors: dobber ja. Transfusion. 2017 Aug;57(8):1949-1955. doi: 10.1111/trf.14183. Epub 2017 Jun 26. Transfusion. 2017. PMID: 28653370
Feedback